Clinical Performance of the Osia 3 Sound Processor Compared with the Osia 2 Sound Processor in Adult Osia Implant Users

Last updated: February 11, 2025
Sponsor: Cochlear
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Hearing Impairment

Deafness

Hearing Loss

Treatment

Cochlear Osia 3 Sound Processor

Cochlear™ Osia® 2 Sound Processor

Clinical Study ID

NCT06338670
CLTD5839
  • Ages > 18
  • All Genders

Study Summary

This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Implanted with a Cochlear Osia Implant (OSI100 or OSI200)

  • Conductive or mixed hearing loss in the implanted ear. Bone conduction threshold 4-frequency pure tone average (PTA4; mean of bone conduction thresholds at 0.5, 1, 2and 4 kHz) ≤ 55 dB HL.

OR Single-Sided Deafness in the implanted ear. Air Conduction threshold 4-frequency pure tone average (PTA4; mean of air conduction thresholds at 0.5, 1, 2 and 3 kHz) ≤ 20 dB HL in the good ear.

  • Aged 18 years or older, at time of consent.

  • Minimum experience of 1 month with the Osia 2 Sound Processor.

  • Fluent speaker in the language used to assess speech perception performance.

  • Willing and able to provide written informed consent.

Exclusion

Exclusion Criteria:

  • Sensitivity to loud sounds.

  • Ongoing infection at or around the sound processor area.

  • Unable or unwilling to comply with the requirements of the clinical investigation asdetermined by the Investigator.

  • Use of ototoxic drugs that could be harmful to the hearing, as judged by theinvestigator

  • Investigator site personnel directly affiliated with this study and/or theirimmediate families; immediate family is defined as a spouse, parent, child, orsibling.

  • Cochlear employees or employees of Contract Research Organisations or contractorsengaged by Cochlear for the purposes of this investigation.

  • Current participation, or participation in another interventional clinicalstudy/trial in the past 30 days, involving an investigational drug or device (unlessthe other investigation was/is a Cochlear sponsored investigation and determined bythe investigator or Sponsor to not impact this investigation).

Study Design

Total Participants: 12
Treatment Group(s): 2
Primary Treatment: Cochlear Osia 3 Sound Processor
Phase:
Study Start date:
July 04, 2024
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • The HEARing CRC

    Melbourne, Victoria 3053
    Australia

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.